Levels of the Stat4 Alpha and Stat4 Beta Isoforms in PBMCs From Patients With Crohn's Disease and Ulcerative Colitis
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202
- Indiana University-Riley Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Children with a new diagnosis of Crohn's Disease and whose physician has not yet initiated corticosteroid treatment (10 Subjects):
- Clinical diagnosis within the previous 21 days
- Above age 7 and younger than age 18
- Signed informed consent statement and assent statement.
- Children with a new diagnosis of Ulcerative Colitis and whose physician has not yet initiated corticosteroid treatment (10 Subjects):
- Clinical diagnosis within the previous 21 days
- Above age 7 and younger than age 18
- Signed informed consent statement and assent statement.
- Children with Crohn's Disease whose physician has initiated Infliximab treatment for the first time (10 Subjects):
- Clinical diagnosis of Crohn's Disease
- Above age 7 and younger that age 18
- Signed informed consent statement and assent statement.
- Children with Ulcerative Colitis whose physician has initiated Infliximab treatment for the first time (10 Subjects):
- Clinical diagnosis of Ulcerative Colitis
- Above age 7 and younger than age 18
- Signed informed consent statement and assent statement.
- Healthy Controls (10 Subjects):
- Above age 7 and younger than age 18
- otherwise healthy, with no intercurrent illness as determined by a member of the study team using the eligibility checklist
- controls will be gender and age (± 2 years) matched to the patient groups described above
- Signed informed consent statement and assent statement
Exclusion Criteria:
- unwilling to give consent for this study.
- child with prior prescription and administration of Infliximab
Study Plan
How is the study designed?
Design Details
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Other: Control
Subjects who have no inflammatory disease who will be age/gender matched controls for the 2 other arms.
|
measuring inflammatory markers and comparing to controls.
|
|
Other: IBD and infliximab
Subjects who have IBD and will be receiving infliximab for the first time.
|
measuring inflammatory markers and comparing to controls.
|
|
Other: Newly Diagnosed IBD
Subjects who are newly diagnosed with IBD and given corticosteroid therapy.
|
measuring inflammatory markers and comparing to controls.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
This study hopes to assess the relative levels of the Stat4a and Stat4β isoforms in PBMCs from patients with Crohn's Disease, ulcerative colitis, or from control patients.
Time Frame: Total duration of treatment will be 20-24 weeks (Arm A and Arm B) or 50-54 weeks (Arm C/ Arm D).
|
Total duration of treatment will be 20-24 weeks (Arm A and Arm B) or 50-54 weeks (Arm C/ Arm D).
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Steven J Steiner, MD, Indiana University
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 0707-69
- IRB # 0707-69
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.